The Magazine for Sleep Professionals
Friday, April 17, 2026
NightWare, Inc. and Exit 156 Capital announced a strategic investment by Exit 156 in NightWare’s ongoing Series C financing. NightWare is the maker of the only FDA-cleared prescription digital therapeutic indicated for nightmare disorder in adults with post-traumatic stress disorder (PTSD). The partnership unites a Minneapolis-based growth-stage digital health company […]
Dreem Health, a leading virtual sleep clinic managed by Sunrise Group, has become the first sleep care service to join Amazon’s Health Benefits Connector. Amazon customers eligible for insurance-covered sleep services can discover and enroll in Dreem Health’s personalized care when browsing for healthcare services. More than 70 million Americans live with sleep […]
ProSomnus Sleep Technologies announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The RPMO2 OSA Device is the first theragnostic device for sleep medicine, incorporating both precision […]
Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, a serious sleep disorder, according to findings recently published in Communications Medicine. The team said their study is the first to provide estimates of whether […]
The American Academy of Sleep Medicine has introduced the Full PSG Autoscoring Certification Program, a new initiative that independently evaluates and certifies autoscoring software that interprets adult sleep stages and events from polysomnography data. The Full PSG Autoscoring Certification Program represents a significant expansion of the AASM’s earlier pilot initiative, which launched […]
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Apnimed, Inc., announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (“HCRx”). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the […]
Even if you’re not one to make New Year’s resolutions, the start of a new year naturally invites reflection on what worked well last year, what needs to change, and what to leave behind. With that spirit of looking ahead in mind, SleepWorld Magazine conducted its inaugural Reader Tech Survey […]
As a sleep physician, one of the most frustrating realities I encounter is not a lack of diagnostic tools, but the barriers patients face in accessing them. Obstructive sleep apnea (OSA) is common, serious, and widely underdiagnosed. Estimates suggest that more than 30 million adults in the United States are […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
